Bibliography
Found 59 results
Filters: Keyword is Humans and Author is Gelman, Benjamin B [Clear All Filters]
CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. J Neurovirol. 2015 ;21(5):559-67.
Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Clin Infect Dis. 2015 ;61(9):1476-84.
Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015 ;60(3):473-80.
Astrocyte elevated gene-1 is a novel modulator of HIV-1-associated neuroinflammation via regulation of nuclear factor-κB signaling and excitatory amino acid transporter-2 repression. J Biol Chem. 2014 ;289(28):19599-612.
. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.
Genetic variation in iron metabolism is associated with neuropathic pain and pain severity in HIV-infected patients on antiretroviral therapy. PLoS One. 2014 ;9(8):e103123.
Gp120 in the pathogenesis of human immunodeficiency virus-associated pain. Ann Neurol. 2014 ;75(6):837-50.
Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders. J Clin Invest. 2014 ;124(10):4459-72.
. HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. J Neurovirol. 2014 ;20(3):209-18.
Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment. J Neuroimmune Pharmacol. 2014 ;9(2):117-32.
. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr. 2013 ;62(1):36-42.
Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 ;68(5):1161-8.
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol. 2013 ;19(4):393-401.
Neurocognitive impairment in HIV-infected individuals with previous syphilis. Int J STD AIDS. 2013 ;24(5):351-5.
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology. 2012 ;433(2):498-505.
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr. 2012 ;59(4):376-81.
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS. 2012 ;26(7):890-3.
Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012 ;18(6):511-20.
Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 ;56(4):1985-9.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 ;66(2):354-7.
Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons. J Neuropsychiatry Clin Neurosci. 2011 ;23(3):316-23.